Revenue Breakdown
Composition ()
No data
Revenue Streams
Ultragenyx Pharmaceutical Inc (RARE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Crysvita royalty revenue, accounting for 40.6% of total sales, equivalent to $64.94M. Other significant revenue streams include Crysvita and Dojolvi. Understanding this composition is critical for investors evaluating how RARE navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Ultragenyx Pharmaceutical Inc maintains a gross margin of 85.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -54.65%, while the net margin is -62.02%. These profitability ratios, combined with a Return on Equity (ROE) of -656.03%, provide a clear picture of how effectively RARE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RARE competes directly with industry leaders such as PAHC and MAZE. With a market capitalization of $2.22B, it holds a leading position in the sector. When comparing efficiency, RARE's gross margin of 85.84% stands against PAHC's 35.70% and MAZE's N/A. Such benchmarking helps identify whether Ultragenyx Pharmaceutical Inc is trading at a premium or discount relative to its financial performance.
